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Abstract
Background: Human papillomavirus type 16 (HPV-16) E5 protein co-operates with epidermal
growth factor to stimulate mitogenesis of murine fibroblasts. Currently, little is known about which
viral amino acids are involved in this process. Using sequence variants of HPV-16 E5 we have
investigated their effects upon E5 transcription, cell-cycling and cell-growth of murine fibroblasts.
Results: We demonstrate that: (i) introduction of Thr64 into the reference E5 sequence of HPV-
16 abrogates mitogenic activity: both were poorly transcribed in NIH-3T3 cells; (ii) substitution of
Leu44Val65  or, Thr37Leu44Val65  into the HPV-16 E5 reference backbone resulted in high
transcription in NIH-3T3 cells, enhanced cell-cycle progression and high cell-growth; and, (iii)
inclusion of Tyr8 into the Leu44Val65 backbone inhibited E5 induced cell-growth and repression of
p21 expression, despite high transcription levels.
Conclusion: The effects of HPV-16 E5 variants upon mitosis help to explain why Leu44Val65 HPV-
16 E5 variants are most prevalent in 'wild' pathogenic viral populations in the UK.
Background
A causal association between high-risk human papilloma-
viruses (HPV) infection – particularly HPV-16 – and cervi-
cal cancer has been established. HPV-16 E5 is a minor
oncoprotein comprising of 83 amino acids and in silica
predictions suggest it comprises of 3 anchor-like α-helices
(residues 8–30, 37–52 and 58–76): with only the first
being sufficient to span a lipid bilayer (Figure 1). A region
within the second helix (residues 41–54) may be the
binding site for the pore sub-unit of 16 KDa ATPase [1],
though others claim it is located between residues 54–78
[2]. HPV-16 E5 is believed to act in the early stages of the
oncogenic process [3-6] and is membrane-associated,
occurring in the Golgi apparatus and endoplasmic reticu-
lum [7].
HPV-16 E5 acts co-operatively with epidermal growth fac-
tor (EGF) to stimulate mitosis. Whilst E5 may, or may not,
bind directly to the EGF-receptor (EGFr) [8,9], it was ini-
tially believed to impair acidification of endosomes via
interaction with 16 KDa ATPase [10,11] and thereby pro-
mote recycling of EGFr to the cell-surface [10]. Others
have suggested: that E5 perturbs EGFr trafficking from
early to late endocytic structures rather than influencing
acidification [12]; or, that E5 uses 16 KDa ATPase as a
chaperone to enter the Golgi [2,13].
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Whatever the initial processes, HPV-16 E5 stimulates c-ras,
causing c-raf to attach to plasma membranes, activating
enzyme cascades through the MEK and MAP kinases,
which in turn migrate to the nucleus to phosphorylate c-
fos transcription factors [14-17]. Ultimately, this permits
assembly of activator protein-1 heterodimers from c-fos
and c-jun and stimulation of mitosis [18-20]. E5 can inter-
dict this pathway via: (i) the induction of protein-kinase C
which activates c-raf [21]; (ii) initiation of c-jun and c-fos
and junB  transcription [22,23]; and (iii), repression of
p21 expression (a cyclin-dependant kinase inhibitor
which causes pocket-protein phosphorylation, release of
E2F and – via de novo synthesis of cyclins A, B and E –
mitosis [23]: Figure 2).
We have previously described HPV-16 E5 variants which
encode novel E5 protein sequences [24]. Here we conjec-
tured that these natural E5 protein variants may have dif-
fering mitogenic properties and that the amino acids
involved in this process might be discernable. This pro-
posal was based upon evidence that certain HPV-16 E5
variants are more prevalent than others in wild viral pop-
ulations in our locality. We detected marked differences in
the ability of individual HPV-16 E5 variants to induce
transcription in stably transfected long-term NIH-3T3 cell
lines, changes in cell-cycle profiles and cell-growth. Some
variants were more mitogenic than the reference isolate of
HPV-16 E5: others which were poorly mitogenic as a
result of either amino acid changes or, low transcriptional
efficiencies. Interestingly, those HPV-16 E5 variants most
frequently detected in our local population (RFLP pattern
2) – and most commonly associated with cervical lesions
– were those which had the greatest mitogenic activity in
vitro.
Results
HPV E5 constructs
HPV-16 E5 variants: Leu44Val65  (AJ244882);
Thr37Leu44Val65  (AJ44863); Thr64(AJ244840) [24];
Tyr8Leu44Val65, (AJ24481); the HPV-16 reference E5
sequence [25,26] and HPV-6b E5 were amplified and
cloned into pcDNA3.1Myc-His. For each HPV-16 E5 vari-
ant, a control construct, containing a TAA 'stop' codon (at
codon position three) was also cloned into
pcDNA3.1Myc-His.
All constructs and 'stop' controls had the correct DNA
sequences after cloning (data not shown). T7 'run-off'
transcripts were prepared and translated in cell-free
wheat-germ expression assays spiked with 35S-labelled
Points at which HPV-16 E5 affects the epidermal growth fac- tor signal transduction pathway Figure 2
Points at which HPV-16 E5 affects the epidermal 
growth factor signal transduction pathway. EGF: epi-
dermal growth factor; EGFr: epidermal growth factor recep-
tor; PKC: protein kinase C; AP-1: activator protein 1.
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Putative structure of HPV-16 E5 Figure 1
Putative structure of HPV-16 E5. Cartoon representa-
tion of the averaged results of multiple secondary structure 
predictions of reference sequence of HPV-16 E5 protein [25, 
26] (e.g. using programmes at http://pref.etfos.hr/split/: data 
not shown) showing the position of the predicted α-helices, 
the proposed voltage gating motif, as well as the amino-acid 
mutations of the natural variants studied.
F
L
T
D 
T
T
L
L
S
A
M
T
L 
N 
A
C
L
C
F
C
V
L
I
L
L
C
V
C
L
R
T
S
V
S
L
L
L
P
Y
T
S
L
I
I
L
V
L
L
L
A
T
I
W
V
I
F
C
R
F
A
S
A
Y
V  
F
I
I
Y
I T
A
H 
T
H
I
L
F
L
P
I
R
F
L
→ → → →Y8 
→ → → →T37
→ → → →L44
→ → → →V65
→ → → →T64
Predicted α α α α-helix
Voltage gating motif [2]
Hydrophilic residueCancer Cell International 2006, 6:19 http://www.cancerci.com/content/6/1/19
Page 3 of 9
(page number not for citation purposes)
cysteine (all have 4 cysteines). Autoradiographs of poly-
acrylamide gel elecprophoresis (PAGE) gels revealed
equivalent levels of in vitro translation for all HPV-16 var-
iants, but no evidence of protein products from the equiv-
alent 'stop' controls (Figure 3A), confirming the fidelity of
TAA ('stop') codons. However, different HPV-16 E5 vari-
ants were transcribed at different levels in stably-trans-
fected (G418-selected) NIH-3T3 cell-lines, with
Tyr8Leu44Val65 being expressed at higher level than either
Thr37Leu44Val65, or Leu44Val65, whilst the Thr64 variant
and reference sequence were transcribed at low level (Fig-
ure 3B). To assist data interpretation, cell-lines for all
'stop' constructs were pooled prior to subsequent experi-
ments.
Co-operation between HPV-16 E5 and EGF
HPV-16 E5 co-operates with EGF to stimulate 3H-thymi-
dine incorporation into DNA of human keratinocytes and
murine fibroblasts [10]. Here we selected to analyse E5-
induced mitosis by cell-cycle profiles as this may provide
more detailed information than levels of 3H-thymidine
incorporation alone (e.g. Figure 4A). To confirm the valid-
ity of this approach we determined whether there was a
synergistic relationship between the reference sequence of
HPV-16 E5 and EGF. Such a relationship between the EGF
and HPV-16 E5 reference sequence was demonstrable (e.g.
Figure 4B), in agreement with a previous study using a 3H-
thymidine readout [10].
E5 variants induce different cell-cycle profiles in the 
presence of EGF
Compared to the 'stop' control, cells transfected with
HPV-6b E5 or the HPV-16 E5 Thr64 variant did not induce
changes in G0G1-phase cell percentages (versus 'stop', both
p > 0.05: Figure 5). All other HPV-16 E5 variants caused
reductions of G0G1-phase (all p < 0.05), this effect being
greatest for Leu44Val65 and the reference isolate (respec-
tively, -16.2% & -15.5% c.f. 'stop'). Modest reductions in
G0G1-phase were observed for the Tyr8Leu44Val65 (-6.1%)
Co-operative effects of HPV-16 E5 and EGF upon the cell- cycle progression Figure 4
Co-operative effects of HPV-16 E5 and EGF upon the 
cell-cycle progression. A: Typical example of cell cycle 
analysis. B: Left to right: 'stop' control (S-phase = 8.25%); 
'stop' control plus epidermal growth factor (EGF: S-phase = 
13%); the reference isolate of HPV-16 (16: S-phase = 13.9%) 
and 16 with EGF (S-phase 37.6%). Results expressed as the 
mean and standard error of the mean for at least three inde-
pendent measurements.
EGF:            - +       - +             - +       - +             - +       - +
E5:               - - +     +              - - +     +             - - +      +
%
o
f
c e l l s
(A)
(B)
0
20
40
60
80
100
G0G1 S                          G2M
DNA content
B
r
d
U
r
d
L
a
b
e
l
l
i
n
g
Expression of E5 protein in vitro and cell line mRNA Figure 3
Expression of E5 protein in vitro and cell line mRNA. 
(A) Autoradiographs of PAGE gels containing in vitro wheat 
germ protein translation products of HPV-16 E5 variants (G) 
and 'stop' codon controls (S), demonstrating 35S-labelled 9.1 
kDa products in the former, but not the latter. +: positive 
(luciferase), and -: negative kit controls. X: 1 ng HPV-16 RNA 
; Y: 0.1 ng HPV-16 RNA. (B) Expression of E5 mRNA 
detected by RT-PCR in transfected cell-lines analysed in the 
presence (+) or absence of reverse transcriptase. B: blank.
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and Thr37Leu44Val65 (-7.4%) variants. The Thr64 variant
had a similar cell-cycle profile to the 'stop'.
Cells containing HPV-6b E5 or the HPV-16 E5 Thr64 vari-
ant resembled the 'stop' in their S-phase profiles (both p
> 0.05). Increases in S-phase were high for the reference
isolate (+ 17.6% c.f. the 'stop') and for the Leu44Val65 var-
iant (+ 12.2%), but lower for Tyr8Leu44Val65 (+9.4%) and
for Thr37Leu44Val65 (+ 6.3%: all p < 0.05). There were also
increases in G2M-phase percentages for cells containing
Leu44Val65 (+ 5.8%: p < 0.05) or Thr37Leu44Val65 (+ 2.8%:
p > 0.05). Other E5 variants induced insignificant
increases of G2M-phase percentages (Thr64 +1.8%; HPV-
6b E5, + 1.6%; reference isolate, + 0.6%; and,
Tyr8Leu44Val65, + 0.2%: all p > 0.05).
E5 variants with increased G2M-phase percentages exhibit 
increased cell-growth
Static analyses of cell-cycle profiles can be difficult to
interpret as the percentage values are inter-dependent var-
iables. Thus, different cell populations could have identi-
cal cell-cycle profiles, but vastly dissimilar growth rates
[27,28]. This problem was addressed by determining cell-
growth at 24, 48 and 72 h in media containing EGF and
minimal (2% v/v) serum supplement. Cells transfected
with Leu44Val65  and Thr37Leu44Val65  variants exhibited
most growth (Figure 6: both p < 0.02 versus the 'stop' at 72
h), whilst the HPV-16 E5 reference isolate induced a
smaller increase in cell number (p < 0.05 versus the 'stop'
at 72 h). Cells containing the Tyr8Leu44Val65 and Thr64 var-
iants, or HPV-6b E5 grew slowly (all, p > 0.05 versus the
'stop' at 72 h). Alternate expression of cell-growth as cell-
doubling times gave equivalent results (e.g. for: Leu44Val65
mean doubling time = 56.6 h; Thr37Leu44Val65 = 49 h;
and, Tyr8 Leu44Val65= 118 h).
Tyr8substitution of HPV-16 E5 is associated with high levels 
of p21 protein
HPV-16 E5 can repress p21 transcription [29]. We thus
determined levels of p21 and cyclin B1 proteins in cells
containing the HPV-16 reference E5 sequence as well as a
variant with a high-growth rate (Leu44Val65) and one with
a low-growth rate (Tyr8Leu44Val65). Cells containing
Tyr8Leu44Val65  maintained high levels of p21 protein
throughout the time course, whereas p21 was much lower
in cells containing the reference isolate and, near undetec-
table for those containing Leu44Val65 (Figure 7). There was
also a delay before cyclin B1 could be detected in cells
containing Tyr8Leu44Val65 as compared to those stably
transfected with the other two E5 proteins. These effects
were not artefactual as levels of protein loaded were simi-
lar as indicated by the β-actin controls.
Discussion
We demonstrate that the reference isolate of HPV-16 E5
can co-operate with EGF to reduce the percentage of cells
in G0G1-phase, increase those in S-phase and increase cell-
growth. HPV-6b E5 exhibited similar though much less
marked changes than the HPV-16 E5 reference isolate, in
agreement with a previous study [10]. In this report we
have examined HPV-16 E5 variant activity under control-
led conditions. Indeed, all were transcriptionally
expressed under the same (T7) promoter and all had a
minimal Kozak sequence [30] inserted around the initial
ATG codon to insure equivalent translational efficiency.
We have used these constructs to significantly extended
previous observations observations on the biologic activ-
ity of HPV-16 E5 by analysing: HPV-16 E5 transcription in
NIH-3T3 cells; cell-cycle progression; and, cell growth.
Effects of E5 variants assayed with EGF upon cell-cycle pro- files Figure 5
Effects of E5 variants assayed with EGF upon cell-
cycle profiles. Results are expressed as the mean percent-
age (plus SEM) of cells in different stages of cell-cycling 
(G0G1, S & G2M) for each of HPV-16 E5 variant tested (solid 
bars), HPV-6b E5 (diagonal stripes), 'stop' constructs (open 
bars). Numbers of experiments: 'stop', n = 21; HPV-6b, n = 6; 
HPV-16, n = 9; Thr64, n = 9; Leu44Val65, n = 18; Thr37 
Leu44Val65, n = 6; and, Tyr8Leu44Val65, n = 11.
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All HPV-16 E5 variants were translated in a cell-free wheat
germ expression system equivalently, however, differ-
ences in E5 transcription were detected between stably
transfected NIH-3T3 variant cell-lines. The HPV-16 E5 ref-
erence sequence and the Thr64 variant were transcribed at
much lower levels than the other variants. Analysis of cell-
growth curves indicated that those with low levels of
mRNA were also those which were slower-growing (HPV-
16 reference and Thr64) and had lower percentages of cells
in G2M phase. In contrast for those transcribed to similar
levels in NIH-3T3 cells, the Leu44Val65  and
Thr37Leu44Val65 variants exhibited high growth but, this
was not the case for Tyr8Leu44Val65. These data suggest
that whilst the addition of Thr37 to the Leu44Val65 back-
bone is neutral, addition of Tyr8 is detrimental to cell-
growth.
All HPV-16 E5 constructs – aside from Thr64 variant –
caused a fall in the percentage of cells in G0G1-phase and
an increase in S-phase, indicating that these variant E5
proteins stimulate passage through the G1/S cell-cycle
checkpoint. Such an increase in the proportion of cells in
S-phase may be advantageous to HPV-16, permitting it to
increase the number of viral copies per cell prior to divi-
sion.
The HPV-16 E5 Leu44Val65 and Thr37Leu44Val65variants,
had greatest percentages of cells in G2M-phase and in
greatest cell-growth. This biological activity may help
explain why these particular E5 (i.e. RFLP pattern 2) vari-
ants are most prevalent (~70%) amongst wild popula-
tions of HPV-16 in inner-city London and most strongly
associated with the presence of cervical lesions [24]. In
contrast, the Tyr8Leu44Val65 variant (which induced low
cell growth) is an RFLP pattern 5 variant which is detected
rarely amongst patients with lesions. Interestingly, the
HPV-16 E5 RFLP pattern 2 HPV-16 E5 variants also co-seg-
regate with nucleotide variation in the long control region
that results in enhanced viral transcription via co-opera-
tion with the human POU transcription factor Brn3A [31].
The Leu44 Val65 substitutions may act to improve the struc-
tural integrity of E5 protein as both are α-helix stabilisers,
whereas isoleucine (present at both sites in the reference
isolate) is a helix destabiliser [32]. However, comparison
of computer-predicted transmembrane regions [33] of the
reference and Leu44Val65 variant did not reveal significant
differences (data not shown). Another possibility is that
the Iso→Val65 change may enhance the activity of two
putative E5 functional domains: the voltage gating motif
(55Ser-x-x-Arg-x-x-x-x-x-Iso-Iso65-Phe-Val-x-x-Pro-x-x-Leu-
x-x-x-His77: [34]), present in the HPV-16 E5 reference iso-
late and all reported mammalian connexins; and, the pro-
posed binding site for 16 kDa ATPase (aa 54–78: [2]).
Conversely, another E5 variant with an adjacent change at
position 64 (Thr64 variant) exhibited an impoverished
biological activity, confounding E5-induced mitogenesis
at the G0/G1 checkpoint.
At least three EGF-independent E5 pathways exist (Figure
1), most notable being the transcriptional repression of
p21 by E5 directly [35] or, indirectly, via E5 induction of
Effect of different variants upon p21 and cyclin B expression Figure 7
Effect of different variants upon p21 and cyclin B 
expression. Expression of p21 and cyclin B proteins over an 
18 h period as determined in western blot experiments using 
β-actin levels as loading controls.
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Cell-growth curves Figure 6
Cell-growth curves. Growth curves for cell lines stably 
transfected with different HPV-16 E5 variants, HPV-6b E5 or 
HPV-16 'stop'. Dotted lines indicate the initial seeding con-
centration, the lower graph was added for clarity. Error bars 
represent the standard error of the mean.
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c-jun  [27,35]. The fact that cells containing the
Tyr8Leu44Val65 variant had the highest levels of p21 pro-
tein implies that the serine usually present at residue 8
may play an essential role in p21 repression. As the refer-
ence isolate and the Leu44Val65 variant respectively exhib-
ited an intermediate and low level of p21 expression it
could also be inferred that residues 44 and 65 may also be
involved in p21 repression.
Accumulation of high levels of p21 protein in cells con-
taining the Tyr8Leu44Val65 variant is also likely to effect
cell-growth by up-regulating apoptosis. Indirect evidence
for this was observed in the cell-growth assays: at 24 h
numbers of Tyr8Leu44Val65 containing cells had fallen to
67% of the seeding concentration (100%), in contrast
those containing Leu44Val65 variant increased to 137%
(data not shown). These differences were even more
marked at 48 h: Tyr8Leu44Val65 cells were down to 54%,
whereas cells containing Leu44Val65 had nearly doubled
(190%).
We also observed a reciprocal association between the lev-
els of p21 and cyclin B1, this has been reported by others
in several cell-systems and may represent a direct inhibi-
tory effect of p21 upon cyclin-B1 biosynthesis [36,37].
Unlike the Tyr8Leu44Val65 variant, insertion of a threonine
(at position 64) into the Leu44Val65 backbone appeared to
have no marked effect.
Conclusion
Using naturally-occurring amino acid sequence variants
of HPV-16 E5 we have demonstrated that: (i) introduction
of Thr64  into the reference E5 sequence abrogates
mitogenic activity most probably through low levels of
transcription; (ii) combined substitution of Leu44Val65
into the E5 reference backbone significantly enhances
cell-cycle progression and cell-growth; (iii) addition of
Thr37  to the Leu44Val65  variant had little effect upon
mitogenic activity; and, (iv) inclusion of Tyr8 into the
Leu44Val65 backbone severely inhibited E5 growth and E5
repression of p21 expression. These effects of HPV-16 E5
amino acid changes upon mitosis may – in part – help to
explain why Leu44Val65 HPV-16 E5 variants are most prev-
alent in 'wild' viral populations in the UK. Thus we sug-
gest amino acids 8 and 64 are critical for the mitogenic
activity of HPV-16 E5.
Methods
HPV samples
HPV-16 E5 variants isolated from clinical samples: Ted
(Leu44Val65, EMBL accession number AJ244882), 9785
(Thr37Leu44Val65, AJ44863) and Twp3 (Thr64, AJ244840)
[24] were studied. Permission for the collection of clinical
specimens was provided by the Research Ethics Commit-
tee of St Thomas' Hospital. In addition, E5 DNA from:
HPV-16 containing CaSki cells (Tyr8Leu44Val65, AJ24481);
the reference isolate of HPV-16 [25,26]; and, from the low
cancer-risk virus HPV-6b were investigated.
Construction of recombinant DNA expression vectors
HPV-16 E5 genes were amplified in polymerase chain
reactions (PCR) using rTth™ DNA polymerase in two sep-
arate reactions, so that E5 open reading frames (ORF)
between nucleotides (nt) 3866 and 4077 (encoding E5
amino acids 6–76) were obtained. The first PCR utilised
an upstream primer
(GGA3836GCTAGCTCACCATGGCAAATCTTGATA3865)
which included an artificial Nhe-1 cut site (underlined)
and a minimal Kozak sequence [30] (3847ACCATGG3853)
this motif was incorporated to promote equivalent trans-
lational efficiency for all constructs and introduces an arti-
ficial alanine residue at codon position two). The second
PCR used a 5' primer (3836GGAGCTAG
CTCACCATGGCATAACTTGATA3865) that also contained
a 'stop' signal (underlined): both PCRs utilised the same
downstream primer which encoded an artificial BamH1
site (4110TACAGGATCCTTATG TAATTAAAAAGCGT
GCATG4078). E5 PCR products were ligated into the Nhe1
and BamH1 sites of pcDNA3.1Myc-His (Invitrogen Ltd.).
The E5 open reading frame (ORF) of HPV-6b E5 was also
PCR amplified (using the upstream primer:
4103TACTATATTGTTGCTAGCCCACCATGGTGCTAA4135
and downstream, 4366TACAAATATAAAAAACGGGG
ATCCCTAATTCATAT4332) and cloned using the same
strategy. Plasmids were transformed into E. Coli JM109
cells and selected by ampicillin resistance. Positive colo-
nies were screened by PCR and then sequenced to confirm
the identity of the DNA inserts.
In vitro translation
A cell-free wheat-germ expression assay (Promega Ltd.)
was used to determine protein translation of T7 mRNA
transcripts with individual reactions supplemented with 5
μl of 35S-labelled cysteine (1 Ci/l: Amersham Interna-
tional Ltd.). Radiolabelled cysteine was selected since all
HPV-16 E5 variants contain 4 cysteine residues. Proteins
were subjected to PAGE (below) and radioactivity
detected by autoradiography.
Preparation of stable NIH-3T3 cells expressing HPV E5 
mRNA
NIH-3T3 cells (ATCC Ltd.) were maintained in Dulbecco's
minimum essential medium supplemented with 40 mM
L-glutamine, 2 × 106 U/l benzyl-penicillin, 2 g/l strepto-
mycin sulphate (DMEM) and 10% (v/v) fetal calf serum
(DMEM/FCS), in a humidified atmosphere of 5% (v/v)
carbon dioxide in air. Cells were transfected with E5 con-
taining plasmids using Lipofectin™ and grown in DMEM/
FCS containing 1 g/l of G418 for 3 weeks (a dose cytotoxic
for non-transfected NIH-3T3 cells within one week). Indi-Cancer Cell International 2006, 6:19 http://www.cancerci.com/content/6/1/19
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vidual colonies of G418-selected cells were isolated and
expanded in DMEM/FCS containing G418 to produce
cell-lines for each variant. Individual cell-lines for each
'stop' construct were pooled. Variant cell-lines and the
'stop pool' were tested intermittently for mycoplasma
infections: all were negative. Cell lines were tested for E5
mRNA expression using an adaption of the method
described by Biswas et al. [5]. Briefly reverse transcriptase
(RT) reactions were primed using the HPV-16 E5 down-
stream primer (4110TACAGGATCCTTATGTA
ATTAAAAAGCGTGCAT4078) with Moloney murine leuke-
mia virus reverse transcriptase then samples were sub-
jected to a nested PCR using internal primers located
within the E5 ORF [5].
Cell-cycle analyses
NIH-3T3 cells transfected with HPV-16 variants, HPV-16
'stop', or HPV-6b were seeded at 0.1 × 106 cells in 5 ml of
DMEM/FCS (containing no G418) into 25 cm3 flasks.
Cells were serum-starved for 24 h in DMEM, media was
then replaced with fresh DMEM with (or without) recom-
binant human EGF (20 μg/l: Boehringer-Mannheim Ltd.)
and cells incubated for a further 24 h. Bromo-deoxyurid-
ine (BrdUrd: 10 μM in DMEM) were added and cells
washed twice by centrifugation through 10 ml of Dul-
becco's phosphate buffered saline (PBS) for 5 min at 200
g at room temperature (rt) and then fixed with 2 ml of ice-
cold aqueuous 70% (v/v) ethanol. Fixative was removed
and cells incubated in 1 ml of 0.1 M HCl containing 1 g/l
pepsin for 12 min at 37°C. Reactions were halted by cen-
trifugation (as above) through, and re-suspension in, PBS.
Murine monoclonal anti-BrdUrd IgG1 heavy and kappa
light chains (Becton-Dickenson Ltd: 250 μl per litre of PBS
which contained 0.5% [v/v] Tween-20™ and 1% [v/v]
FCS) was added for 1 h at rt, cells were washed with PBS
and then incubated for 30 min at rt in the dark with fluor-
osceine-isothiocyanate (FITC) labelled Fab2 fragments of
rabbit anti-mouse immunoglobulin (Dako Ltd.) at rt.
After a further wash in PBS cells were re-suspended in, and
stained with, 1 ml of propidium iodide/RNAse solution
(50 g propidium iodide and 200 g RNAse/l PBS) for 15
min at rt before analysis on a Becton-Dickenson flow
cytometer (FACSCalibur™). Data from 10,000 events (i.e.
stained cells) were analysed (for a minimum of four
times) for each reading after separation of single intact
nuclei from debris and cell-clumps by gating on an FL2
area/width plot. Cells were then characterised on the basis
of detection of green (FITC) and red (propidium iodide)
fluorescence.
Cell-growth
Cells were grown in 2% (v/v) in DMEM containing 2% (v/
v) fetal calf serum, supplemented with EGF (20 μg/l), after
seeding at a density of 0.1 × 106 cells in 20 cm3 Petri
dishes. Cells were fed daily with fresh media containing
EGF and cultures harvested at 24, 48 and 72 h by detach-
ment from Petri dishes by exposure to Versene (5 ml for 2
min at 37°C). One millilitre of DMEM/FCS was added to
inactivate the trypsin then cells were pelleted by centrifu-
gation (200 g for 15 min at rt). Cell pellets were re-sus-
pended in DMEM/FCS and viable cell numbers
determined immediately by trypan-blue exclusion stain-
ing [38].
Western blots
NIH-3T3 cells (0.1 × 106 cells in 5 ml of DMEM/FCS con-
taining no G418) into 20 cm3 Petri dishes and left over-
night. Cells were serum-starved for 24 h in DMEM, grown
in DMEM supplemented with EGF (as above), then har-
vested over an 18 h period. Cells were lysed by suspension
in RIPA buffer and cellular debris removed by centrifuga-
tion at 10,000 g for 30 sec at rt. Protein concentrations
were determined using a commercial assay (BioRad Ltd.)
and adjusted to enable 5 μg of total protein to be added to
each well of a PAGE gel. Cellular proteins were subjected
to PAGE under reducing conditions through a 4–12%
Tris/glycine gradient gel (Novex Ltd.) and blotted onto
Hybond-P™ membranes (Amersham International Ltd.).
Each blot was next cut into strips containing the proteins
of interest: cyclin B1 (60 kDa), β-actin (42 kDa) and p21
(21 kDa). Strips were blocked overnight at rt using 5% (w/
v) dried milk powder (Marvel™, Premier Brands UK Ltd.)
in Tris-buffered saline/Tween™ (20 mM Tris [hydroxyme-
thyl]-amino methane; 0.2 M sodium chloride and 0.1%
[v/v] Tween-20™, pH 7.5: TBS-T).
Blot strips were washed three times with TBS-T then incu-
bated for 1 h at rt with rabbit anti-β-actin (1/1000 dilu-
tion), mouse anti-p21 (2.5 mg/l) or, mouse anti-cyclin B1
(2 mg/l: Pharminogen Ltd.) antibodies. After two washes
in TBS-T strips were immersed in the appropriate horse-
radish peroxidase-labelled secondary antibody (sheep
anti-mouse immunoglobulin or donkey anti-rabbit
immunoglobulin: Amersham International Ltd. each at a
dilution of 1/250) for 1 h at rt. Bound antibody was
detected using an ECL-plus™ chemiluminescence kit and
ECL Hyperfilm™ (Amersham International Ltd.).
Statistical analyses
Students' t-tests were used to assist the interpretation of
data.
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